Effects of lifestyle interventions on epigenetic signatures of liver fat : Central randomized controlled trial
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd..
BACKGROUND AND AIMS: In the CENTRAL trial context, we found diverse liver fat dynamics in response to different dietary interventions. Epigenetic mechanisms may contribute to the intraindividual variation. Moreover, genetic factors are involved in developing nonalcoholic fatty-liver disease (NAFLD), a disease reflected by an increase in intrahepatic fat (IHF). In this exploratory analysis, we primarily aimed to examine the effect of lifestyle interventions on DNA-methylation of NAFLD related genes associated with IHF.
METHODS: For 120 participants from the CENTRAL trial, an 18-month regimen of either low-fat (LF) or Mediterranean-low carbohydrate (MED/LC) diets, with or without physical activity (PA+/PA-), was instructed. Magnetic resonance imaging was used to measure IHF%, which was analysed for association with CpG specific DNA-methylation levels of 41 selected candidate genes. Single-nucleotide polymorphisms known to be associated with NAFLD within the studied genes were genotyped by TaqMan assays.
RESULTS: At baseline, participants (92% men; body mass index = 30.2 kg/m2 ) had mean IHF of 10.7% (59% NAFLD). Baseline-IHF% was inversely correlated with DNA-methylation at individual CpGs within AC074286.1, CRACR2A, A2MP1, FARP1 (P < .05 for all multivariate models). FARP1 rs9584805 showed association with IHF, with the prevalence of NAFLD and baseline methylation level of the CpG site (cg00071727) associated with IHF%. Following 18-month lifestyle intervention, differential DNA-methylation patterns were observed between diets at cg14335324 annotated to A2MP1 (P = .04, LF vs. MED/LC), and differential DNA-methylation between PA groups within AC074286.1, CRACR2A, and FARP1 CpGs (P < .05 for all, PA-vs. PA+).
CONCLUSIONS: This study suggests epigenetic markers for IHF and potential epigenetic remodeling after long-term lifestyle interventions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Liver international : official journal of the International Association for the Study of the Liver - 41(2021), 9 vom: 04. Sept., Seite 2101-2111 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yaskolka Meir, Anat [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.08.2021 Date Revised 19.08.2021 published: Print-Electronic ClinicalTrials.gov: NCT01530724 Citation Status MEDLINE |
|---|
| doi: |
10.1111/liv.14916 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32491234X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32491234X | ||
| 003 | DE-627 | ||
| 005 | 20231225191326.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/liv.14916 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1083.xml |
| 035 | |a (DE-627)NLM32491234X | ||
| 035 | |a (NLM)33938135 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yaskolka Meir, Anat |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of lifestyle interventions on epigenetic signatures of liver fat |b Central randomized controlled trial |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.08.2021 | ||
| 500 | |a Date Revised 19.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT01530724 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND AND AIMS: In the CENTRAL trial context, we found diverse liver fat dynamics in response to different dietary interventions. Epigenetic mechanisms may contribute to the intraindividual variation. Moreover, genetic factors are involved in developing nonalcoholic fatty-liver disease (NAFLD), a disease reflected by an increase in intrahepatic fat (IHF). In this exploratory analysis, we primarily aimed to examine the effect of lifestyle interventions on DNA-methylation of NAFLD related genes associated with IHF | ||
| 520 | |a METHODS: For 120 participants from the CENTRAL trial, an 18-month regimen of either low-fat (LF) or Mediterranean-low carbohydrate (MED/LC) diets, with or without physical activity (PA+/PA-), was instructed. Magnetic resonance imaging was used to measure IHF%, which was analysed for association with CpG specific DNA-methylation levels of 41 selected candidate genes. Single-nucleotide polymorphisms known to be associated with NAFLD within the studied genes were genotyped by TaqMan assays | ||
| 520 | |a RESULTS: At baseline, participants (92% men; body mass index = 30.2 kg/m2 ) had mean IHF of 10.7% (59% NAFLD). Baseline-IHF% was inversely correlated with DNA-methylation at individual CpGs within AC074286.1, CRACR2A, A2MP1, FARP1 (P < .05 for all multivariate models). FARP1 rs9584805 showed association with IHF, with the prevalence of NAFLD and baseline methylation level of the CpG site (cg00071727) associated with IHF%. Following 18-month lifestyle intervention, differential DNA-methylation patterns were observed between diets at cg14335324 annotated to A2MP1 (P = .04, LF vs. MED/LC), and differential DNA-methylation between PA groups within AC074286.1, CRACR2A, and FARP1 CpGs (P < .05 for all, PA-vs. PA+) | ||
| 520 | |a CONCLUSIONS: This study suggests epigenetic markers for IHF and potential epigenetic remodeling after long-term lifestyle interventions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a DNA-methylation | |
| 650 | 4 | |a Diet | |
| 650 | 4 | |a genetic variation | |
| 650 | 4 | |a nonalcoholic fatty liver disease | |
| 650 | 4 | |a physical activity | |
| 650 | 7 | |a CRACR2A protein, human |2 NLM | |
| 650 | 7 | |a Calcium-Binding Proteins |2 NLM | |
| 700 | 1 | |a Keller, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Müller, Luise |e verfasserin |4 aut | |
| 700 | 1 | |a Bernhart, Stephan H |e verfasserin |4 aut | |
| 700 | 1 | |a Tsaban, Gal |e verfasserin |4 aut | |
| 700 | 1 | |a Zelicha, Hila |e verfasserin |4 aut | |
| 700 | 1 | |a Rinott, Ehud |e verfasserin |4 aut | |
| 700 | 1 | |a Kaplan, Alon |e verfasserin |4 aut | |
| 700 | 1 | |a Gepner, Yftach |e verfasserin |4 aut | |
| 700 | 1 | |a Shelef, Ilan |e verfasserin |4 aut | |
| 700 | 1 | |a Schwarzfuchs, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Ceglarek, Uta |e verfasserin |4 aut | |
| 700 | 1 | |a Stadler, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Blüher, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Stumvoll, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Kovacs, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Shai, Iris |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Liver international : official journal of the International Association for the Study of the Liver |d 2003 |g 41(2021), 9 vom: 04. Sept., Seite 2101-2111 |w (DE-627)NLM124147356 |x 1478-3231 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2021 |g number:9 |g day:04 |g month:09 |g pages:2101-2111 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/liv.14916 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2021 |e 9 |b 04 |c 09 |h 2101-2111 | ||